Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Post-Transplant Lymphoproliferative Disease
Atara BiotherapeuticsCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Post-Transplant Lymphoproliferative Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Washington University School of Medicine | Phase 2 | BBB |
Rituximab Jennifer Amengual | Phase 2 | BB |
Fludarabine City of Hope Medical Center | Phase 2 | BB |
Cyclosporin A National Cancer Institute (NCI) | Phase 2 | BB |
Methotrexate National Cancer Institute (NCI) | Phase 2 | BB |
View all 47 →
Same molecule, other indications
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →